A study from Memorial Sloan-Kettering Cancer Center, New York sheds light on the “obesity paradox” seen with renal cell carcinoma while at the same time demonstrating the emerging value of genomics in understanding cancer and other diseases.
The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.
In the lawsuit, the urologist contended the circumcision was properly performed and the patient’s curvature was due to a previously asymptomatic Peyronie’s condition, which was exacerbated after the circumcision procedure.
The advantages that robotic technologies bring to prostate procedures, partial nephrectomies, and other surgeries that can involve complex reconstruction are not readily apparent in simple extirpative surgeries such as radical nephrectomy. This raises two questions: Are robots being used in radical nephrectomies and if so, why?
Patients with chronic kidney disease who undergo robot-assisted partial nephrectomy for kidney cancer have minimal loss of renal function—a smaller amount even than patients with normal kidney function, according to researchers at Henry Ford Hospital in Detroit, who say their study is the largest of its kind.
The first phase II study to investigate the use of the targeted therapy everolimus (Afinitor) for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease.
The tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.